Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-10-21
2008-08-19
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S227800, C514S235800, C514S252110, C514S253010, C514S253050, C514S254010, C514S255010, C540S597000, C544S060000, C544S121000, C544S357000, C544S360000, C544S363000, C544S372000, C544S391000
Reexamination Certificate
active
07414047
ABSTRACT:
Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
REFERENCES:
patent: 3714179 (1973-01-01), Tweit
patent: 3886160 (1975-05-01), Tweit
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5569659 (1996-10-01), Reitz
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5900422 (1999-05-01), Ali
patent: 6596706 (2003-07-01), Kikuchi et al.
patent: 2004/0110746 (2004-06-01), Apodaca et al.
patent: 0 186 817 (1986-07-01), None
patent: 0624584 (1998-08-01), None
patent: 0978512 (2000-02-01), None
patent: 02306237 (1990-12-01), None
patent: HEI 10-59954 (1998-03-01), None
patent: 93/04694 (1993-03-01), None
patent: 9525443 (1995-09-01), None
patent: 9626196 (1996-08-01), None
patent: 9805292 (1998-02-01), None
patent: 9924475 (1999-05-01), None
patent: WO 99/42458 (1999-08-01), None
patent: WO 02/012190 (2002-02-01), None
patent: WO 02/012214 (2002-02-01), None
patent: WO 02/024695 (2002-03-01), None
patent: WO 02/076925 (2002-10-01), None
patent: WO 03/004480 (2003-01-01), None
patent: WO 03/024928 (2003-03-01), None
patent: WO 03/024929 (2003-03-01), None
patent: WO 03/031432 (2003-04-01), None
patent: WO 03/050099 (2003-06-01), None
patent: 03/055866 (2003-07-01), None
patent: WO 03/064411 (2003-08-01), None
patent: 2005/035534 (2005-04-01), None
patent: 2005/040144 (2005-05-01), None
Albengres, E. et al. Systemic Antifungal Agents. Drug Safety (Feb. 1998) 18(2):83-97.
Ali, S.M. et al. Design, Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists. J. Med. Chem. (1999) 42(5):903-909.
Arrang, J.-M. et al. Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (Apr. 1983) 302:832-837.
Ash, A.S.F.; Schild, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1966) 27:427-439.
Back, D.J.: Tjia, J.F. Inhibition of Tolbutamide Metabolism by Substituted Imidazole Drugs In Vivo: Evidence for a Structure-Activity Relationship. Br. J. Pharmacol. (1985) 85:121-126.
Barnes, J.C. et al. The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release In Vivo. Soc. Neurosci. Abstr. (1993) 19:1813.
Bioworld Today, Mar. 2, 1999, p. 3.
Black, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (Apr. 1972) 236:385-390.
Ding, Y.-S. et al. Synthesis of HIgh Specific Activity (+)- and (−)-6-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction. J. Med. Chem. (1991) 34(2):767-771.
Ganellin, C.R. et al. Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists. Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) (1998) 331:395-404.
Garbarg, M. et al. S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist. J. Pharmacol. Exp. Ther. (1992) 263(1):304-310.
Gliatech Inc. Press Release Nov. 5, 1998.
Gonzalez, F. Garcia, et al. Synthesis of 3-aryl(alkyl)-4-(D-arabino-tetrahydroxybutyl)imidazoline-2-thiones, Carbohydrate Research, 22(2), 436-40 (English) 1968.
Ichinose, M.; Barnes, P.J. Histamine H3-Receptors Modulate Nonadrenergic Noncholinergic Neural Bronchoconstriction in Guinea-Pig In Vivo. Eur. J. Pharmacol. (1989) 174(1):49-55.
Imamura, M. et al. Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release. J. Pharmacol. Exp. Ther. (1994) 271(3):1259-1266.
Jones, R.G. Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboylates fromGlycine and Substituted Glycine Esters. J. Am. Chem. Soc. (1949) 71:644-647.
Jordaan, A., Arndt, R.R., The Synthesis of 1-Methyl-5-(α-indolyl)imidazole and 1-Methyl-2-ethylthiol-5-(α-indolyl)imidazole. Journal of Heterocyclic Chemistry 5(5), 723-5 (English) 1968.
Kapetanovic, I.M.; Kupferberg, H.J. Nafimidone, an Imidazole Anticonvulsant, and Its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine. Drug Metab. Dispos. (1984) 12(5):560-564.
Korte, A. et al. Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by N alpha-Methylhistamine. Biochem. Biophys. Res. Commun. (May 1990) 168(3):979-986.
Krause, M. et al. Medicinal Chemistry of Histamine H3 Receptor Agnoists; In The Histamine H3 Receptor—A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 175-196.
Lavrijsen, K. et al. Induction Potential of Antifungals Containing an Imidazole or Triazole Moiety. Biochem. Pharmacol. (1986) 35(11):1867-1878.
Leurs, R. et al. The Medicinal Chemistry and Therapeutic Potentials of Ligands of the Histamine H3 Receptor. Prog. Drug Res. (1995) 45:107-165.
Leurs, R. et al; “Therapeutic potential of histamine H3 recepto agonists and antagonists” Trends n Pharmacological sciences, Elsevier Trends Journal, Cambridge, BG, vol. 19, No. 5, May 1, 1998; pp. 177-184, XP004121095.
Lin, J.-S. et al. Involvement of Histaminergic Neurons in Arousal Mechanisms Demonstrated with H3-Receptor Ligands in the Cat. Brain Res. (1990) 523:325-330.
Linney, I.D. et al. Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists. J. Med. Chem. (2000) 43(12):2362-2370.
Lovenberg, T.W. et al. Cloning and Functional Expression of the Human Histamine H3 Receptor. Mol. Pharmacol. (1999) 55:1101-1107.
Lovenberg, T.W. et al. Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293(3):771-778.
Machidori, H. et al. Zucker Obese Rats: Defect in Brain Histamine Control of Feeding. Brain Res. (1992) 590:180-186.
McLeod, R.L. et al. Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist. Soc. Neurosci. Abstr. (1996) 22:2010.
Meier, G. et al. Piperidino-Hydrocarbon Compounds as Novel Non-Imidazole Histamine H3-Receptor Antagonists. Bioorg. Med. Chem. (2002) 10:2535-2542.
Monti, J.M. et al. Effects of Selective Activation or Blockade of the Histamine H3 Receptor on Sleep and Wakefulness. Eur. J. Pharmacol. (1991) 205(3):283-287.
Morisset, S. et al. High Constitutive Activity of Native H3 Receptors Histamine Neurons in Brain. Nature (Dec. 2000) 408:860-864.
Oda, T. et al. Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes. J. Biol. Chem. (2000) 275(47):36781-36786.
Panula, P. et al. Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease. Soc. Neurosci. Abstr. (1995) 21:1977.
Phelps, M.E. Positron Emission Tomography Provides Molecular Imaging of Biological Processes. Proc. Natl. Acad. Sci. (2000) 97(16):9226-9233.
Phillips, J.G.; Ali, S.M. Medicinal Chemistry of Histamine H3 receptor Antagonists; In The Histamine H3 Receptor—A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 197-222.
Phillips, J.G. et al. Chapter 4, Recent Advances in Histamine H3Receptor Agents. Ann. Reports in Med. Chem., 31, 1998, pp. 31-40.
Rouleau, A. et al. Bioavailibility, Antinociceptive and Antiinflammatory Properties of BP 2-94, a Histamine H3 Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. (1997) 281(3):1085-1094.
Sabbatini, Renato.M.E., The Cyclotron and PET. In Brain & Mind an electronic magazine about Neuroscience [online], Mar. 1997. Retrived from the internet, <http:www.epub.org.br/cm
01/pet/petcyclo.htm.
Schlicker, E.; Marr, I. The Moderate Affinity of Clozapine at H3 Receptors Is Not Shared by Its Two Major Metabolites and by Structurally Related and Unrelated Atypical Neuroleptics. Naunyn-Schmiedeberg's Arch. Pharmacol. (1996) 353:290-294.
Sheets, J.J.
Apodaca Richard L.
Jablonowski Jill A.
Ly Kiev S.
Shah Chandravadan R.
Swanson Devin M.
Coleman Brenda L
Janssen Pharmaceutica N.V.
LandOfFree
Piperazinyl and diazapanyl benzamides and benzthioamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazinyl and diazapanyl benzamides and benzthioamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyl and diazapanyl benzamides and benzthioamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4010552